Metabolomics Pilot Study on Intensive Care Acquired Muscle Weakness in Polytrauma (MIRACLE-II Study)
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Metabolomics
研究概览
简要总结
In this mono-center pilot trial, polytrauma patients admitted to intensive care will be included. Investigators are going to take blood and muscle samples at respecified time points to do metabolic, histological and molecular testing.
Aim of the study is to investigate (1) changes of the blood metabolome in patients with ICUAW (intensive care unit acquired weakness) and (2) identify metabolic components who are responsible for ICUAW or can be used as marker for ICUAW.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •acute polytrauma patient
- •age ≥ 18 years old
- •expected intensive care stay ≥ 3 days
- •American Society of Anesthesiologists classification I or II
排除标准
- •patient had received cardiopulmonary resuscitation
- •limitation of therapy or comfort care
结局指标
主要结局
Metabolomics
时间窗: a median of 14 days
Blood Metabolome will be isolated from blood samples. All samples will be screened for changes in the blood metabolome during muscle wasting (i.e. Intensive Care Unit Acquired Weakness) using mass spectrometry
次要结局
- Muscle histology(a median of 14 days)
- Phosphoproteomics(a median of 14 days)
研究者
Stefan Schaller
Principal Investigator
Technical University of Munich